CN1711085A — 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物
Assigned to Yamanouchi Pharmaceutical Co Ltd · Expires 2005-12-21 · 20y expired
What this patent protects
(R)-2-(2-氨基噻唑-4-基)-4′-[2-[(2-羟基-2-苯乙基)氨基]乙基]乙酸酰基苯胺或其盐在“离体的大鼠膀胱平滑肌松弛测试”中显示出潜在的膀胱松弛作用,在“大鼠节律性膀胱收缩测量试验”中剂量依赖性降低节律性膀胱收缩的收缩频率,此外,在“对环磷酰胺诱导的膀胱活动过度模型大鼠的排尿功能测量试验”中延长排尿间隔。由于这些效果,上面的化合物用于治疗膀胱活动过度。
USPTO Abstract
(R)-2-(2-氨基噻唑-4-基)-4′-[2-[(2-羟基-2-苯乙基)氨基]乙基]乙酸酰基苯胺或其盐在“离体的大鼠膀胱平滑肌松弛测试”中显示出潜在的膀胱松弛作用,在“大鼠节律性膀胱收缩测量试验”中剂量依赖性降低节律性膀胱收缩的收缩频率,此外,在“对环磷酰胺诱导的膀胱活动过度模型大鼠的排尿功能测量试验”中延长排尿间隔。由于这些效果,上面的化合物用于治疗膀胱活动过度。
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.